Literature DB >> 35861871

A longitudinal analysis of the effect of anemia on executive functions in children with mild to moderate chronic kidney disease.

Nisha S Singh1, Rebecca J Johnson2, Matthew B Matheson3, Joann Carlson4, Stephen R Hooper5, Bradley A Warady6.   

Abstract

BACKGROUND: Children with chronic kidney disease (CKD) are at risk for cognitive dysfunction. The aim of this study was to investigate associations between executive functions (EF), anemia, and iron deficiency.
METHODS: A total of 688 children > 6 years of age enrolled in the Chronic Kidney Disease in Children (CKiD) study who underwent evaluation for EF were included. Hemoglobin (Hgb) was characterized as low (1st-5th percentile) or very low (< 1st percentile) compared to normative values for age, sex, and race irrespective of erythropoiesis-stimulating agent (ESA) usage. Longitudinal analysis was conducted using consecutive visit pairs, with anemia status defined as new onset, resolved, or persistent. Linear mixed models with random intercept were used and adjusted for key covariates.
RESULTS: Anemia was present in 41% of children, and median Hgb was 11.8 gm/dl. New onset anemia was associated with lower digit span total score (- 0.75, 95% CI - 1.36, - 0.15, p = 0.01). Persistent anemia was associated with lower scores on color-word inhibition/switching (β =  - 0.98; 95% CI - 1.78, - 0.18, p = 0.02). Errors of omission were significantly higher (worse) in those with persistent anemia (β = 2.67, 95% CI 0.18, 5.17, p = 0.04). Very low Hgb levels were significantly associated with lower color-word inhibition/switching scores (β =  - 1.33, 95% CI - 2.16, - 0.51; p = 0.002). Anemia and low GFR were associated with lower category fluency scores compared to non-anemic subjects with higher GFR (β =  - 1.09, 95% CI - 2.09, - 0.10, p = 0.03).
CONCLUSIONS: The presence of anemia, in addition to its severity and duration in children with CKD, is associated with poorer scores on select measures of EF. A higher resolution version of the Graphical abstract is available as Supplementary information.
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  Anemia; Chronic kidney disease; Neurocognition; Pediatric

Year:  2022        PMID: 35861871     DOI: 10.1007/s00467-022-05682-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  5 in total

1.  Neurocognitive functioning of children and adolescents with mild-to-moderate chronic kidney disease.

Authors:  Stephen R Hooper; Arlene C Gerson; Robert W Butler; Debbie S Gipson; Susan R Mendley; Marc B Lande; Shlomo Shinnar; Alicia Wentz; Matthew Matheson; Christopher Cox; Susan L Furth; Bradley A Warady
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-07       Impact factor: 8.237

2.  Casual blood pressure and neurocognitive function in children with chronic kidney disease: a report of the children with chronic kidney disease cohort study.

Authors:  Marc B Lande; Arlene C Gerson; Stephen R Hooper; Christopher Cox; Matt Matheson; Susan R Mendley; Debbie S Gipson; Cynthia Wong; Bradley A Warady; Susan L Furth; Joseph T Flynn
Journal:  Clin J Am Soc Nephrol       Date:  2011-06-23       Impact factor: 8.237

3.  Neurocognitive, Social-Behavioral, and Adaptive Functioning in Preschool Children with Mild to Moderate Kidney Disease.

Authors:  Stephen R Hooper; Arlene C Gerson; Rebecca J Johnson; Susan R Mendley; Shlomo Shinnar; Marc B Lande; Matthew B Matheson; Debbie S Gipson; Bruce Morgenstern; Bradley A Warady; Susan L Furth
Journal:  J Dev Behav Pediatr       Date:  2016-04       Impact factor: 2.225

4.  Memory and executive functions in pediatric chronic kidney disease.

Authors:  Debbie S Gipson; Stephen R Hooper; Peter J Duquette; Crista E Wetherington; Kurt K Stellwagen; Tonya L Jenkins; Maria E Ferris
Journal:  Child Neuropsychol       Date:  2006-12       Impact factor: 2.500

Review 5.  Epoetin and cognitive function.

Authors:  A R Nissenson
Journal:  Am J Kidney Dis       Date:  1992-07       Impact factor: 8.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.